GameStop Eyes eBay Acquisition as Stock Prices Surge After Hours 
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
Apple Q2 2026 Earnings Surge as iPhone 17 Sales Drive Record Revenue 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
Coles Group Q3 Sales Rise Driven by Supermarkets and E-Commerce Growth 
Google Secures Pentagon AI Deal for Classified Projects 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
Alphabet Earnings Surge on AI Growth, Cloud Revenue, and Strong Search Performance 
Hugel Inc. has forged a distribution partnership with Sihuan Pharmaceutical for its Letybo botulinum toxin product after becoming the first South Korean brand approved to enter the Chinese market.
China’s National Medical Products Administration recently approved Hugel's Letybo for local sales.
Sihuan Pharmaceutical, which has a network of over 10,000 hospitals and medical institutions, will expedite Hugel's entry into the Chinese botox market.
Hugel hopes to take a 30 percent share within three years of the product launch and is aspiring to become the top botox brand in the country.
The South Korean biopharmaceutical firm is also eyeing to enter the European market in 2021 and the US market in 2022.
The market is estimated to be worth 1.75 trillion won by 2025.
Hugel is now one of the four companies, including US’ Allergan, French company Ipsen’s Dysport, and Chinese company Lanzhou Institute of Biological Products’ Hengli, authorized to trade in the Chinese botox market.
Due to its continued economic growth and increasing attention for beauty and appearance, China is expected to have increased demand for BTX products.
